Document is current
Any future updates will be listed below
-
Authors
Ferastraoaru, D. https://orcid.org/0000-0002-9799-4800
Bax, H. J. https://orcid.org/0000-0003-0432-4160
Bergmann, C. https://orcid.org/0000-0002-2076-8813
Capron, M. https://orcid.org/0000-0001-5625-5158
Castells, M.
Dombrowicz, D. https://orcid.org/0000-0002-0485-8923
Fiebiger, E. https://orcid.org/0000-0003-3385-0100
Gould, H. J. https://orcid.org/0000-0003-0411-688X
Hartmann, K. https://orcid.org/0000-0002-4595-8226
Jappe, U.
Jordakieva, G. https://orcid.org/0000-0001-5884-8256
Josephs, D. H. https://orcid.org/0000-0002-5610-9123
Levi-Schaffer, F. https://orcid.org/0000-0003-0620-2810
Mahler, V. https://orcid.org/0000-0001-6471-1811
Poli, A.
Rosenstreich, D. https://orcid.org/0000-0003-0612-3450
Roth-Walter, F. https://orcid.org/0000-0001-5005-9228
Shamji, M. https://orcid.org/0000-0003-3425-3463
Steveling-Klein, E. H. https://orcid.org/0000-0002-4303-0571
Turner, M. C. https://orcid.org/0000-0002-6431-1997
Untersmayr, E. https://orcid.org/0000-0002-1963-499X
Karagiannis, S. N. https://orcid.org/0000-0002-4100-7810
Jensen-Jarolim, E. https://orcid.org/0000-0003-4019-5765
-
Funding
Funding for this research was provided by:
European Academy of Allergy and Clinical Immunology (Task Force)
- License Information
-
More Information
Article History
Received: 5 June 2020
Accepted: 11 June 2020
First Online: 17 July 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: All authors have read and approved the Position Paper. Any potential conflicts of interests are listed here: EJJ: Erika Jensen-Jarolim declares inventorship in patents on allergen immunotherapy formulation with Biomedical International R + D, Vienna, Austria, of which she is shareholder. She received honoraria for presentations from Allergy Therapeutics, AllergoPharma, Bencard, Meda, Roxall, ThermoFisher, and consulted previously for MediGene, Germany, Novartis, for Allergy Therapeutics and Dr. Schär. VM: Vera Mahler indicates, that the views expressed in this Position Paper are the personal views of the author as an expert in the field of allergology and may not be understood or quoted as being made on behalf of or reflecting the position of the respective national competent authorities, the European Medicines Agency, or one of its committees or working parties. She reports having no COI within the last 3 years. FRW: Franziska Roth-Walter declares inventorship in patents on allergen immunotherapy formulation with Biomedical International R + D GmbH, Vienna, Austria. SNK: Sophia N. Karagiannis is founder and shareholder of Epsilogen Ltd. and has received funds from Espilogen Ltd. Sophia N. Karagiannis holds a patent on anti-tumour IgE antibodies. ESH: Esther Steveling declares honoraria as an expert in advisory board from Bencard and travel grant to attend the yearly European Academy of Allergy and Clinical Immunology congress from ALK and Bencard. HJB: Heather J Bax declares financial support from Epsilogen Ltd. MCT: Turner Michelle C is funded by a Ramón y Cajal fellowship (RYC-2017-01892) from the Spanish Ministry of Science, Innovation and Universities and co-funded by the European Social Fund. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
